MedTrace Logo

A Phase II Study of 610 in Participants With Severe Eosinophilic Asthma

NCT05528679 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2022-09-06

No results posted yet for this study

Summary

This study will assess the efficacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.

Conditions

Interventions

DRUG

610 100mg

100mg administered subcutaneously Q4W

DRUG

610 300mg

300mg administered subcutaneously Q4W

DRUG

placebo

administered subcutaneously Q4W

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xin Zhou, MD · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

  • Qinghong Zhou, MD · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

  • Min Zhang, MD · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-30
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05528679 on ClinicalTrials.gov